Correvio Pharma (CORV) Misses Q1 EPS by 3c, Revenues Miss

Correvio Pharma (NASDAQ: CORV) reported Q1 EPS of ($0.23), $0.03 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.89 million.

"2019 is off to a strong start with first quarter revenues up 16% year-over-year in local currencies," commented Mark H.N. Corrigan, MD, CEO of Correvio. "Our first quarter revenues from Xydalba and Zevtera doubled year-over-year. Looking ahead, we remain on track to resubmit the New Drug Application seeking approval in the U.S. for BrinavessTM as a new treatment for adult patients with recent onset atrial fibrillation during the second quarter of 2019."

For earnings history and earnings-related data on Correvio Pharma (CORV) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Z Squared outlines AI power strategy and Paradox Data acquisition
• U.S. Physical Therapy names Nchacha Etta as CFO, effective Sept. 2026